Desloratadine

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H19ClN2
Molecular Weight	310.821
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

ClC1=CC2=C(C=C1)C(=C3CCNCC3)C4=C(CC2)C=CC=N4

InChI

InChIKey=JAUOIFJMECXRGI-UHFFFAOYSA-N

InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2

HIDE SMILES / InChI

Molecular Formula	C19H19ClN2
Molecular Weight	310.821
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11243504
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf

Desloratadine is an active, descarboethoxy metabolite of loratadine. It acts by selective inhibition of H1 histamine receptor and thus provides relief to patients with allergic rhinitis and chronic idiopathic urticaria. Desloratadine was approved by FDA and it is currently marketed under the name Clarinex (among the others).

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H1 receptor 313 Target ID: CHEMBL231 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	Antagonist 2760		0.87 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Seasonal allergic rhinitis 63 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	Palliative	Approved 8360	CLARINEX Approved Use Desloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria. Launch Date 1.00889277E12
Perennial allergic rhinitis 47 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	Palliative	Approved 8360	CLARINEX Approved Use Desloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria. Launch Date 1.00889277E12
Chronic idiopathic urticaria 11 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	Palliative	Approved 8360	CLARINEX Approved Use Desloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria. Launch Date 1.00889277E12

C_max

Value	Dose	Co-administered	Analyte	Population
4 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DESLORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
56.9 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DESLORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
27 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DESLORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
84.5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DESLORATADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
1.25 mg 1 times / day steady, oral Dose: 1.25 mg, 1 times / day Route: oral Route: steady Dose: 1.25 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf Page: p. 25	unhealthy, 2-11 years n = 48 Health Status: unhealthy Age Group: 2-11 years Sex: M+F Population Size: 48 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf Page: p. 25	Disc. AE: Somnolence, Abdominal pain... AEs leading to discontinuation/dose reduction: Somnolence (1 patient) Abdominal pain (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf Page: p. 25
45 mg 1 times / day multiple, oral Highest studied dose Dose: 45 mg, 1 times / day Route: oral Route: multiple Dose: 45 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21165lbl.pdf	healthy, adult Health Status: healthy Age Group: adult Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21165lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21165lbl.pdf

AEs

AE	Significance	Dose	Population
Abdominal pain	1 patient Disc. AE	1.25 mg 1 times / day steady, oral Dose: 1.25 mg, 1 times / day Route: oral Route: steady Dose: 1.25 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf Page: p. 25	unhealthy, 2-11 years n = 48 Health Status: unhealthy Age Group: 2-11 years Sex: M+F Population Size: 48 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf Page: p. 25
Somnolence	1 patient Disc. AE	1.25 mg 1 times / day steady, oral Dose: 1.25 mg, 1 times / day Route: oral Route: steady Dose: 1.25 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf Page: p. 25	unhealthy, 2-11 years n = 48 Health Status: unhealthy Age Group: 2-11 years Sex: M+F Population Size: 48 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021300s000_Clarinex_MedR.pdf Page: p. 25

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1709	inhibitor 1752	substrate 1193 inhibitor 1837	inhibitor 1599

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1509 CYP2C8 901 CYP2C19 1463 CYP2B6 799 CYP3A4/5 273 UGT1A1 204 UGT1A3 84 UGT1A4 77 UGT1A6 108 UGT1A9 116 UGT2B7 146 UGT2B10 25 UGT2B15 64 UGT2B17 18 UGT1A7 21 UGT1A8 36 UGT1A10 32 UGT2B4 19 P-gp 1437	CYP1A2 1032 CYP2B6 660 CYP1A1 348 CYP2C19 985 UGT2B10 127 P-gp 1527

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1673	inhibitor 3240 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	no
CYP2C19 1537	inhibitor 3240 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	no
CYP2C8 955	inhibitor 3240 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	no
CYP2C9 1803	inhibitor 3240 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	no
UGT1A1 254	inhibitor 3240 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT1A3 93	inhibitor 3240 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT1A4 80	inhibitor 3240 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT1A6 141	inhibitor 3240 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT1A7 23	inhibitor 3240 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT1A8 48	inhibitor 3240 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT1A9 121	inhibitor 3240 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT2B15 64	inhibitor 3240 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
UGT2B7 157	inhibitor 3240 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	no
P-gp 1626	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/11454724/	not significant [IC50 43 uM]
UGT2B10 27	inhibitor 3240 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	strong [Ki 1.3 uM]
CYP2B6 985	inhibitor 3240 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	weak [Inhibition 10 uM]
CYP2D6 1875	inhibitor 3240 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	weak [Inhibition 10 uM]
CYP3A4/5 330	inhibitor 3240 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,5	weak [Inhibition 10 uM]
UGT1A10 41	inhibitor 3240 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	weak [Inhibition 10 uM]
UGT2B17 20	inhibitor 3240 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	weak [Inhibition 10 uM]
UGT2B4 19	inhibitor 3240 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 4,6	weak [Inhibition 10 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A1 348	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=19 Page: 19.0	likely
CYP1A2 1032	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=10 Page: 10.0	likely
CYP2B6 660	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=10 Page: 10.0	likely
CYP2C19 985	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=19 Page: 19.0	likely	no (pharmacogenomic study) Comment: pharmacogenotype 2C19 does not correlate with systemic exposure Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=19 Page: 19.0
CYP2D6 1193	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=10 Page: 10.0	likely	no (pharmacogenomic study) Comment: lack of correlation in between 2D6 genotype and 3-OH DCL formation Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=10 Page: 10.0
CYP3A4 1709	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=10; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=33 Page: 10.0	likely	weak (co-administration study) Comment: Coadministration of ketonconazole, mean drug Cmax and AUC0-24 values at steady state were increased by 29-45% and 21-39%, respectively; Coadministration with erythromycin, mean drug Cmax and AUC 0-24 at steady state were increased by 24% and 14%, respectively. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=10; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=33 Page: 10.0
UGT2B10 127	substrate 3326 Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 1.0	yes
P-gp 1527	substrate 3326 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388404/	yes	weak (co-administration study) Comment: Coadministration of ketonconazole, mean drug Cmax and AUC0-24 values at steady state were increased by 29-45% and 21-39%, respectively; Coadministration with erythromycin, mean drug Cmax and AUC 0-24 at steady state were increased by 24% and 14%, respectively. Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388404/

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1632	inhibitor 1613 Sources: https://pubmed.ncbi.nlm.nih.gov/11243504/#:~:text=Preclinical%20studies%20also%20show%20that,in%20preclinical%20and%20clinical%20studies.

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:291342	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:291342
ChemicalBook	CB3462564	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3462564
MolPort	MolPort-000-883-875	https://www.molport.com/shop/molecule-link/MolPort-000-883-875
Selleck Chemicals	desloratadine	http://www.selleckchem.com/products/desloratadine.html
ZINC	ZINC000000001261	http://zinc15.docking.org/substances/ZINC000000001261
eMolecules	877481	https://www.emolecules.com/cgi-bin/more?vid=877481

PubMed

Title	Date	PubMed
Advances in allergy management.	2002	12492727
Impact and modulation of nasal obstruction.	2002	12492726
Therapeutic points of intervention and clinical implications: role of desloratadine.	2002	12492724
Investigation of an enhanced resolution triple quadrupole mass spectrometer for high-throughput liquid chromatography/tandem mass spectrometry assays.	2002	12391581
Lack of clinically relevant interaction between desloratadine and erythromycin.	2002	12169044
A pharmacokinetic profile of desloratadine in healthy adults, including elderly.	2002	12169042
Oral bioavailability of desloratadine is unaffected by food.	2002	12169041
The new antihistamines--desloratadine and levocetirizine: a review.	2002 Dec	12851991
[The place of new antihistamines in allergy management. Apropos of desloratadine].	2002 Dec	12575624
Treatment of allergic rhinitis.	2002 Dec 16	12517578
Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion.	2002 Nov	12452207
Clinical pharmacology of H1-antihistamines in the skin.	2002 Nov	12417888
Desloratidine for the treatment of chronic urticaria.	2002 Oct	12548327
Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitis.	2002 Oct	12392387
Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis.	2002 Oct	12372132
Efficacy of once-daily desloratadine/pseudoephedrine for relief of nasal congestion.	2002 Sep-Oct	12476542
Severe hepatotoxicity after application of desloratadine and fluconazole.	2003	12975558
Desloratadine: an update of its efficacy in the management of allergic disorders.	2003	12962522
Chronic urticaria: a role for newer immunomodulatory drugs?	2003	12688835
Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma.	2003 Apr	12740532
Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial.	2003 Apr	12664016
Pharmacokinetic properties of single-dose loratadine and ambroxol alone and combined in tablet formulations in healthy men.	2003 Aug	14512130
Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine.	2003 Aug	12952117
Studies on performance and sleepiness with the H1-antihistamine, desloratadine.	2003 Aug	12924753
Assessing satisfaction with desloratadine and fexofenadine in allergy patients who report dissatisfaction with loratadine.	2003 Aug 13	12917016
Desloratadine: a nonsedating antihistamine.	2003 Feb	12549956
The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study.	2003 Jan 6	12515585
Pharmacokinetics of loratadine and its active metabolite descarboethoxyloratadine in healthy Chinese subjects.	2003 Jul	12852841
Validation of a sensitive and automated 96-well solid-phase extraction liquid chromatography-tandem mass spectrometry method for the determination of desloratadine and 3-hydroxydesloratadine in human plasma.	2003 Jul 25	12860030
[Safety of new antihistamines].	2003 Jun	14524292
[Clinical aspects of anti-inflammatory action of antihistamines].	2003 Jun	14524290
The effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis.	2003 Jun	12814463
Effects of mediator antagonism on mannitol and adenosine monophosphate challenges.	2003 Jun	12801313
Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure.	2003 Jun	12757447
Gateways to clinical trials. March 2003.	2003 Mar	12731460
Double-stranded RNA viruses in a mycocinogenic strain of Cystofilobasidium infirmominiatum.	2003 Mar	12702247
Decongestant effects of antihistamines: a class effect?	2003 Mar	12642858
P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists.	2003 Mar	12584158
First do no harm: managing antihistamine impairment in patients with allergic rhinitis.	2003 May	12743547
[Multicenter study of the effectiveness and tolerability of desloratadine in seasonal allergic rhinitis].	2003 May 25	12847854
Loratadine, desloratadine and pregnancy: don't use, risk of hypospadias.	2003 Oct	14619900
Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment.	2003 Oct	14530791
Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin.	2003 Oct	14520518
Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin.	2003 Oct	12968983
Reliable and specific high-performance liquid chromatographic method for simultaneous determination of loratadine and its metabolite in human plasma.	2003 Oct 25	14552827
[Modern antihistaminics against allergic rhinitis. Better breathing without side effects].	2003 Oct 30	14655512
Improvements in simulated real-world relevant performance for patients with seasonal allergic rhinitis: impact of desloratadine.	2004 Apr	15005765
Inhibition of cold urticaria by desloratadine.	2004 Jan	14754651
Anti-inflammatory activity of H1-receptor antagonists: review of recent experimental research.	2004 Jan	14741075
Gateways to clinical trials.	2004 Jan-Feb	14988742

Patents

Sample Use Guides

In Vivo Use Guide

Adults and Adolescents 12 Years of Age and Over: take 5 mg tablet once daily. Children 6 to Years of Age: take 2.5 mg tablet once daily. Children 12 Months to 5 Years of Age: take 1.25 mg tablet once daily. Children 6 to 11 Months of Age: 1 mg tablet once daily.

Route of Administration: Oral

In Vitro Use Guide

Nasal epithelial cells (activated by 1 uM of histamine) were treated with 10 uM of desloratadine and the inhibitory activity of the drug on expression of ICAM-1 and HLA-DR was studied.

Substance Class	Chemical Created by `admin` on `Thu Jul 06 21:23:58 UTC 2023` Edited by `admin` on `Thu Jul 06 21:23:58 UTC 2023`
Record UNII	FVF865388R
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Desloratadine

Official Name

English

8-Chloro-5,6-dihydro-11-(piperidin-4-ylidene)-11H-benzo[5,6]cyclohepta[1,2-b]pyridine)

Systematic Name

English

DESLORATADINE RATIOPHARM (AUTHORIZED: RHINITIS, URTICARIA)

Brand Name

English

DESLORATADINE RATIOPHARM

Brand Name

English

DENOSIN

Brand Name

English

desloratadine [INN]

Common Name

English

5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)-

Systematic Name

English

DASSELTA

Brand Name

English

NSC-759824

Code

English

DESLORATADINE [MART.]

Common Name

English

LORATADINE RELATED COMPOUND A [USP IMPURITY]

Common Name

English

NEOCLARITYN

Brand Name

English

DESLORATADINE ACTAVIS (AUTHORIZED: RHINITIS, URTICARIA)

Brand Name

English

DESLORATADINE [MI]

Common Name

English

DESLORATADINE [VANDF]

Common Name

English

DESLORATADINE [USP-RS]

Common Name

English

RUPATADINE FUMARATE IMPURITY B [EP IMPURITY]

Common Name

English

DESLORATADINE [USP MONOGRAPH]

Common Name

English

CLARINEX

Brand Name

English

DESCARBOETHOXYLORATADINE

Common Name

English

DESLORATADINE ACTAVIS

Brand Name

English

DESLORATADINE TEVA (AUTHORIZED: RHINITIS, URTICARIA)

Brand Name

English

DESLORATADINE [ORANGE BOOK]

Common Name

English

CLARINEX-D COMPONENT DESLORATADINE

Common Name

English

OPULIS

Brand Name

English

SCH-34117

Code

English

AZOMYR

Brand Name

English

ALLEX

Brand Name

English

Desloratadine [WHO-DD]

Common Name

English

DESLORATADINE TEVA

Brand Name

English

LORATADINE IMPURITY D [EP IMPURITY]

Common Name

English

AERIUS

Brand Name

English

DESLORATADINE [JAN]

Common Name

English

LORATADINE RELATED COMPOUND A [USP-RS]

Common Name

English

DESLORATADINE [EMA EPAR]

Common Name

English

DESLORATADINE [EP MONOGRAPH]

Common Name

English

DESLORATADINE [USAN]

Common Name

English

DESLORATADINE COMPONENT OF CLARINEX-D

Common Name

English

Classification Tree Code System Code

EMA ASSESSMENT REPORTS

DESLORATADINE TEVA (AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)